Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Recently published
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Recently published
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need Help? E-mail the JCI Insight
  • Top
  • Supplemental material
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article
Advertisement

Corrigendum Free access | 10.1172/jci.insight.126617

Identification of CD163 as an antiinflammatory receptor for HMGB1-haptoglobin complexes

Huan Yang, Haichao Wang, Yaakov A. Levine, Manoj K. Gunasekaran, Yongjun Wang, Meghan Addorisio, Shu Zhu, Wei Li, Jianhua Li, Dominique P.V. de Kleijn, Peder S. Olofsson, H. Shaw Warren, Mingzhu He, Yousef Al-Abed, Jesse Roth, Daniel J. Antoine, Sangeeta S. Chavan, Ulf Andersson, and Kevin J. Tracey

Find articles by Yang, H. in: JCI | PubMed | Google Scholar

Find articles by Wang, H. in: JCI | PubMed | Google Scholar

Find articles by Levine, Y. in: JCI | PubMed | Google Scholar

Find articles by Gunasekaran, M. in: JCI | PubMed | Google Scholar

Find articles by Wang, Y. in: JCI | PubMed | Google Scholar

Find articles by Addorisio, M. in: JCI | PubMed | Google Scholar

Find articles by Zhu, S. in: JCI | PubMed | Google Scholar

Find articles by Li, W. in: JCI | PubMed | Google Scholar

Find articles by Li, J. in: JCI | PubMed | Google Scholar

Find articles by de Kleijn, D. in: JCI | PubMed | Google Scholar

Find articles by Olofsson, P. in: JCI | PubMed | Google Scholar

Find articles by Warren, H. in: JCI | PubMed | Google Scholar

Find articles by He, M. in: JCI | PubMed | Google Scholar

Find articles by Al-Abed, Y. in: JCI | PubMed | Google Scholar

Find articles by Roth, J. in: JCI | PubMed | Google Scholar

Find articles by Antoine, D. in: JCI | PubMed | Google Scholar

Find articles by Chavan, S. in: JCI | PubMed | Google Scholar

Find articles by Andersson, U. in: JCI | PubMed | Google Scholar

Find articles by Tracey, K. in: JCI | PubMed | Google Scholar

Published December 20, 2018 - More info

Published in Volume 3, Issue 24 on December 20, 2018
JCI Insight. 2018;3(24):e126617. https://doi.org/10.1172/jci.insight.126617.
Copyright © 2018, American Society for Clinical Investigation
Published December 20, 2018 - Version history
View PDF

Related article:

Identification of CD163 as an antiinflammatory receptor for HMGB1-haptoglobin complexes
Huan Yang, … , Ulf Andersson, Kevin J. Tracey
Huan Yang, … , Ulf Andersson, Kevin J. Tracey
Haptoglobin binds and sequesters the damage-associated molecular pattern (DAMP) inflammatory mediator HMGB1 through a CD163-dependent mechanism.
Research Article Hepatology Immunology

Identification of CD163 as an antiinflammatory receptor for HMGB1-haptoglobin complexes

  • Text
  • PDF
Abstract

Secreted by activated cells or passively released by damaged cells, extracellular HMGB1 is a prototypical damage-associated molecular pattern (DAMP) inflammatory mediator. During the course of developing extracorporeal approaches to treating injury and infection, we inadvertently discovered that haptoglobin, the acute phase protein that binds extracellular hemoglobin and targets cellular uptake through CD163, also binds HMGB1. Haptoglobin-HMGB1 complexes elicit the production of antiinflammatory enzymes (heme oxygenase-1) and cytokines (e.g., IL-10) in WT but not in CD163-deficient macrophages. Genetic disruption of haptoglobin or CD163 expression significantly enhances mortality rates in standardized models of intra-abdominal sepsis in mice. Administration of haptoglobin to WT and to haptoglobin gene-deficient animals confers significant protection. These findings reveal a mechanism for haptoglobin modulation of the inflammatory action of HMGB1, with significant implications for developing experimental strategies targeting HMGB1-dependent inflammatory diseases.

Authors

Huan Yang, Haichao Wang, Yaakov A. Levine, Manoj K. Gunasekaran, Yongjun Wang, Meghan Addorisio, Shu Zhu, Wei Li, Jianhua Li, Dominique P.V. de Kleijn, Peder S. Olofsson, H. Shaw Warren, Mingzhu He, Yousef Al-Abed, Jesse Roth, Daniel J. Antoine, Sangeeta S. Chavan, Ulf Andersson, Kevin J. Tracey

×

Original citation: JCI Insight. 2016;1(7):e85375. https://doi.org/10.1172/jci.insight.85375

Citation for this corrigendum: JCI Insight. 2018;3(24):e126617. https://doi.org/10.1172/jci.insight.126617

The Editors posted an Expression of Concern for this article following notification that an investigative committee at the University of Liverpool had data integrity concerns regarding the NMR experiments contributed by Daniel J. Antoine, shown in Figure 1, E and F. The Journal has published a corrected version of this article, and the authors have provided a description of changes, which is below:

In our published work, we reported that HMGB1 binds to haptoglobin, the acute phase protein that binds extracellular hemoglobin. We based our conclusions on multiple lines of evidence: (a) haptoglobin-conjugated beads captured HMGB1 after hemoperfusion of septic rats (Figure 1A); (b) immune-precipitation assays using pure proteins confirmed binding of haptoglobin and HMGB1 (Figure 1B); (c) surface plasmon resonance analysis (BIACore) using pure proteins revealed the binding interaction of haptoglobin and HMGB1 had an affinity (Kd) around 64 nM (Figure 1C); (d) there are three redox isoforms of HMGB1. We showed that haptoglobin effectively binds fully reduced and disulfide isoforms of HMGB1, but not the fully oxidized sulfonyl HMGB1, as revealed by immune-precipitation assay (Figure 1D); and (e) we observed HMGB1-haptoglobin complexes in human serum from patients with severe sepsis by coimmunoprecipitation using haptoglobin-specific antibodies (Figure 1G in the original article; Figure 1E in the corrected article).

In Figures 1, E and F, an analysis of HMGB1 isoforms by NMR was undertaken in a separate laboratory by Daniel J. Antoine. In November 2018, we learned that these data were likely compromised. We contacted the Journal, and the Editorial Board agreed to publish an updated online version of the article. In the updated version, all conclusions based on Figure 1, E and F, have been removed. The Journal has also published an online version of the original article with the unreliable statements crossed out (Supplemental File, Redaction). We believe that the major conclusions of the study are accurate and that the corrected paper is reliable.

Supplemental material

View Supplemental data

Footnotes

See the related article at Identification of CD163 as an antiinflammatory receptor for HMGB1-haptoglobin complexes.

Version history
  • Version 1 (December 20, 2018): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need Help? E-mail the JCI Insight

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Supplemental material
  • Footnotes
  • Version history
Advertisement
Advertisement
Follow JCI Insight:
Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts